<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/196A7E43-E653-4989-82D1-8C8054CCD508"><gtr:id>196A7E43-E653-4989-82D1-8C8054CCD508</gtr:id><gtr:firstName>Danny</gtr:firstName><gtr:surname>McAuley</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_G1002460"><gtr:id>ECBF459D-1E5D-454E-A3CC-11E2C7212B58</gtr:id><gtr:title>Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunctio</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_G1002460</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Scientific Abstract|The first section details the plan for undertaking a phase 2 randomised trial to test the effectiveness and safety of simvastatin in ALI/ARDS (Objective 1). The second section describes the studies of biological markers of inflammation and lung injury to provide insight into the mechanism of action of simvastatin in ALI/ARDS (Objective 2).|Objective 1:|Design: This will be a prospective, randomised, double-blind, placebo-controlled phase 2 multi-centre, clinical study of simvastatin in patients with ALI/ARDS.|Setting: Fourteen adult general ICUs.|Target population: Mechanically ventilated, intubated adult patients with ALI/ARDS defined according to the American-European Consensus Conference definition. Exclusion criteria will include: age &amp;lt;16 years old; more than 48 hours from the onset ALI; pregnancy; creatine kinase (CK) &amp;gt;10 x upper limit of the normal range; transaminases &amp;gt;5 x upper limit normal; CYP3A4 inhibitors as listed in the detailed project description; severe renal impairment (calculated creatinine clearance less than 30ml/minute) not receiving renal replacement therapy, severe liver disease (Childs Pugh score &amp;gt; 11); domiciliary mechanical ventilation; current or recent treatment (within 2 weeks) with statins; participation in other trials within 30 days; contraindication to enteral drug administration; and consent declined.|Interventions: Patients will be randomised to receive once daily simvastatin 80mg or identical placebo tablet administered enterally via a feeding tube or orally for up to 28 days.|Outcomes and duration of follow-up: The primary clinical efficacy outcome will be ventilator free days (VFDs). VFDs are the number of days after initiating unassisted breathing to day 28 after randomisation, assuming a subject survives for at least 48 hours after initiating unassisted breathing. VFDs represent a validated outcome measure which quantifies the number of days alive and free from mechanical ventilation. It remains the most useful and validated clinical outcome measure in phase 2 clinical trials in ALI/ARDS.|The following secondary outcomes will also be assessed: 1) pulmonary dysfunction; as measured by oxygenation index (OI), which measures both impaired oxygenation and the amount of mechanical ventilation delivered; 2) non-pulmonary organ failure as measured by the SOFA score; 3) 28 day mortality; 4) safety and tolerability as assessed by the frequency of serious adverse events and suspected unexpected serious adverse reactions (SUSARs); 5) Health-related quality of life (QoL) as assessed using the self-administered EuroQol-5D (EQ-5D) postal questionnaire; and 6) cost effectiveness.|Patient data will be recorded in the case record form daily by the research nurse until day 28. Follow-up at 3, 6 and 12 months will use a postal questionnaire containing the EQ-5D and resource use questions for the health economic analysis.|Objective 2:|We will test the hypothesis that simvastatin decreases neutrophil activation, pro-inflammatory cytokines and adhesion molecule expression, and will explore whether this occurs by reduced NFkB activation. Furthermore, we will investigate whether simvastatin reduces plasma levels of cell-specific indices of activation and injury to the alveolar epithelium and the endothelium. We shall also assess simvastatins effect on lung extracellular matrix destruction.|Blood and urine will be taken on days 0, 3, 7, 14 and 28.|Sample size: The mean (standard deviation; SD) VFDs in 432 patients with ALI/ARDS was 12.7 (10.6) days. On the basis of published data, a conservative treatment effect of 20% has been estimated for this study. A 20% treatment effect represents a 2.6 day increase in VFDs. A 2.6 day increase in VFDs either as a result of improved mortality and/or decreased duration of ventilation would be of major importance. A sample size of 524 subjects (262 in each group) will have 80% power at a two-tailed significance level of 0.05 to detect a 20% difference</gtr:technicalSummary><gtr:fund><gtr:end>2015-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>964437</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>'Local Talent, Global Impact' Medical Research public talk</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>EDE68E2D-F7CF-4F13-8660-756BC7CB4203</gtr:id><gtr:impact>Approximately 300 local people attended this evening meeting where 4 medical researchers presented to the public about the research taking place at Queen's and its impact on patient outcomes. My presentation was on 'Finding New Treatments for Failing Lungs'

Recognition of the importance of acute lug injury.</gtr:impact><gtr:outcomeId>ezeMw7itujb</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.qub.ac.uk/home/ResearchandEnterprise/BusinessNetworks/OtherLectures/2012Lectures/MedicalResearchatQueensDiscoverytoRecovery/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Clinical Trial Targets Acute Respiratory Distress Syndrome with Cholesterol Drug</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>0890942D-D314-4129-8EC5-2BBE8D3D82F0</gtr:id><gtr:impact>Media interest in novel treatments for ARDS</gtr:impact><gtr:outcomeId>mT9yJ8g3V13</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>240000</gtr:amountPounds><gtr:country>Ireland, Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Health Research Awards</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Health Research Board (HRB)</gtr:fundingOrg><gtr:id>021743E2-6376-4749-951E-C39195E4DD16</gtr:id><gtr:outcomeId>TLoXAEsVwuh0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15600</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Proximity to Discovery</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>87B7BFFE-983F-492F-92AF-A1065F1D58A2</gtr:id><gtr:outcomeId>56de327b4de2a9.56616815</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>115953</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Opportunity led scheme</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Department of Health Social Services and Public Safety (DHSSPS)</gtr:fundingOrg><gtr:id>6AD51C0C-671A-4114-9939-2E3D214ABF8F</gtr:id><gtr:outcomeId>MCTKprNpLn6</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>913841</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Fellowship Programme</gtr:department><gtr:description>NIHR clinician scientist award (Shyamsundar)</gtr:description><gtr:end>2020-04-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>CVD/5137/15</gtr:fundingRef><gtr:id>05153DB9-E350-4406-A927-2DFD8C9E4B26</gtr:id><gtr:outcomeId>56de47ebc16d56.77737206</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5600</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC EMINENT scheme</gtr:description><gtr:end>2018-11-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>F7BAC7CF-A015-4B93-885D-843389DFE9C1</gtr:id><gtr:outcomeId>58c93893eecbc6.86786796</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>226000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>RfPB</gtr:description><gtr:end>2016-11-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>PB-PG-0211-24123</gtr:fundingRef><gtr:id>DFDE53D3-490B-4969-9440-EE3AA3F333FD</gtr:id><gtr:outcomeId>F7zSHhMZgW8</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in systematic review</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>09DE59C4-742D-4308-8768-B5E35A802461</gtr:id><gtr:outcomeId>58c935119b4059.27762066</gtr:outcomeId><gtr:type>Citation in systematic reviews</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in clinical guideline</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Scandinavian clinical practice guideline on fluid and drug therapy in adults with acute respiratory distress syndrome</gtr:guidelineTitle><gtr:id>AF974566-0912-4562-94E9-549C39BCA78F</gtr:id><gtr:outcomeId>58c935dd13caa3.31420148</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Simvastatin therapy, although safe and associated with minimal adverse effects, did not improve clinical outcomes in patients with ARDS.</gtr:description><gtr:id>CB6A7349-4020-4C97-8A9F-4DD9BB639CCC</gtr:id><gtr:impact>Completed phase 2/3 trial in patients with ALI.</gtr:impact><gtr:outcomeId>AXV2LAraQHB</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>HARP-2</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>This study is a randomised, double-blind, placebo controlled trial to investigate if simvastatin reduces delirium in the critically ill. 142 patients will randomly allocated to be given either simvastatin or a placebo.</gtr:description><gtr:id>637A0ACD-7367-497E-89AF-59BC8F359F56</gtr:id><gtr:impact>Ongoing phase 2 trial in patients with delirium.</gtr:impact><gtr:outcomeId>WDrKDvKZNHc</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>MoDUS</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Samples collected from HARP-2 to be used in project to inform endotypes in ARDS</gtr:description><gtr:id>5A86A224-957C-4CF1-B756-2F74CF03092D</gtr:id><gtr:impact>Funding from MRC EMINENT scheme to inform endotypes in ARDS</gtr:impact><gtr:outcomeId>58c939f05dd744.79141564</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>HARP-2 samples</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>0A6D75F9-1FAE-4CE9-9FFD-3501A5B2778F</gtr:id><gtr:title>Statin therapy for acute respiratory distress syndrome: an individual patient data meta-analysis of randomised clinical trials.</gtr:title><gtr:parentPublicationTitle>Intensive care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8535f766bbb6432807d33374859ef465"><gtr:id>8535f766bbb6432807d33374859ef465</gtr:id><gtr:otherNames>Nagendran M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0342-4642</gtr:issn><gtr:outcomeId>58c44f998812c3.52960554</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71828CF2-ACCF-487D-B358-8A9CA01267CC</gtr:id><gtr:title>How outcomes are defined in clinical trials of mechanically ventilated adults and children.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/119a0874da92103ba21bef832c59b55c"><gtr:id>119a0874da92103ba21bef832c59b55c</gtr:id><gtr:otherNames>Blackwood B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>5462728f304263.20093649</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>645AA166-EAF7-47E2-AEE2-A84DE2EB5D9E</gtr:id><gtr:title>Simvastatin to reduce pulmonary dysfunction in patients with acute respiratory distress syndrome: the HARP-2 RCT</gtr:title><gtr:parentPublicationTitle>Efficacy and Mechanism Evaluation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84269857d3fdf895b886b2eb8e85e0cb"><gtr:id>84269857d3fdf895b886b2eb8e85e0cb</gtr:id><gtr:otherNames>McAuley D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a99bb1d1e94a8.16790331</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4176C3FC-A6DE-4137-BF73-51E49D70BE60</gtr:id><gtr:title>Statins in patients with sepsis and ARDS: is it over? We are not sure.</gtr:title><gtr:parentPublicationTitle>Intensive care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84269857d3fdf895b886b2eb8e85e0cb"><gtr:id>84269857d3fdf895b886b2eb8e85e0cb</gtr:id><gtr:otherNames>McAuley D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0342-4642</gtr:issn><gtr:outcomeId>5a9a7bc6649116.16996474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F4C37CB-D636-4DDF-AEAD-432F444D3251</gtr:id><gtr:title>Simvastatin for patients with acute respiratory distress syndrome: long-term outcomes and cost-effectiveness from a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Critical care (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45f7ce3b5a53b18d3b8fe6ebad7d3e0f"><gtr:id>45f7ce3b5a53b18d3b8fe6ebad7d3e0f</gtr:id><gtr:otherNames>Agus A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1364-8535</gtr:issn><gtr:outcomeId>5a99b82bb40929.44085569</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2A2FCE6-AB62-4356-964D-730F065EFE7B</gtr:id><gtr:title>Reply to Letter: &amp;quot;Effect of Simvastatin on Physiological and Biological Outcomes in Patients Undergoing Esophagectomy: A Randomized Placebo-controlled Trial&amp;quot;.</gtr:title><gtr:parentPublicationTitle>Annals of surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57f812c9c4e876799f448057e9bddbc9"><gtr:id>57f812c9c4e876799f448057e9bddbc9</gtr:id><gtr:otherNames>Shyamsundar M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0003-4932</gtr:issn><gtr:outcomeId>58c44f9b344a49.67462776</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14987EA8-31C0-4703-AC76-8D6D42EDE7CA</gtr:id><gtr:title>Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in acute lung injury to reduce pulmonary dysfunction (HARP-2) trial: study protocol for a randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae21e9c1839a8b5535f2713c32c95fec"><gtr:id>ae21e9c1839a8b5535f2713c32c95fec</gtr:id><gtr:otherNames>McAuley DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_12580_20_22985805</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD58765C-B0D5-45C5-BFB4-EE32D2872976</gtr:id><gtr:title>Effect of simvastatin on physiological and biological outcomes in patients undergoing esophagectomy: a randomized placebo-controlled trial.</gtr:title><gtr:parentPublicationTitle>Annals of surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57f812c9c4e876799f448057e9bddbc9"><gtr:id>57f812c9c4e876799f448057e9bddbc9</gtr:id><gtr:otherNames>Shyamsundar M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0003-4932</gtr:issn><gtr:outcomeId>5462728e86d597.73520847</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05DCC70A-A035-4E84-AB92-867E5479B453</gtr:id><gtr:title>Acute respiratory distress syndrome.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a17671420ae54897b6ad7c56308487e3"><gtr:id>a17671420ae54897b6ad7c56308487e3</gtr:id><gtr:otherNames>Sweeney RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>58c44f99af7531.25547575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD4F1C5C-8816-4153-B11E-ED7D18A90DFE</gtr:id><gtr:title>Evaluation of early administration of simvastatin in the prevention and treatment of delirium in critically ill patients undergoing mechanical ventilation (MoDUS): a randomised, double-blind, placebo-controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac588ec976e6b4c01d6bb3b7feecb88f"><gtr:id>ac588ec976e6b4c01d6bb3b7feecb88f</gtr:id><gtr:otherNames>Page VJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>5a99bb73c33567.54754731</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0051CA87-5F6C-435A-AC02-31CAA6AAC2F8</gtr:id><gtr:title>Pharmacological treatments in ARDS; a state-of-the-art update.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/efd8e5d7249c011b0f94d537e2b24e5a"><gtr:id>efd8e5d7249c011b0f94d537e2b24e5a</gtr:id><gtr:otherNames>Boyle AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>pm_12580_20_23957905</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27D1664C-3D7F-4AC2-BE19-9ED504B2DACF</gtr:id><gtr:title>Simvastatin pre-treatment improves survival and mitochondrial function in a 3-day fluid-resuscitated rat model of sepsis.</gtr:title><gtr:parentPublicationTitle>Clinical science (London, England : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa9b0cfd67767a90c17aed0303f46c0b"><gtr:id>aa9b0cfd67767a90c17aed0303f46c0b</gtr:id><gtr:otherNames>Morel J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0143-5221</gtr:issn><gtr:outcomeId>58c44f98e21629.67519380</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FBEF301-26E6-4944-BBFF-BE66CA1D569F</gtr:id><gtr:title>Is there a need for emerging drugs for the acute respiratory distress syndrome?</gtr:title><gtr:parentPublicationTitle>Expert opinion on emerging drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acf3c6c2858661f2eb4de7dc6119444d"><gtr:id>acf3c6c2858661f2eb4de7dc6119444d</gtr:id><gtr:otherNames>Fitzgerald M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1472-8214</gtr:issn><gtr:outcomeId>5462729006da04.33151482</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85059467-5096-4CC2-948E-41C3AC1314F4</gtr:id><gtr:title>Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e370902ae10c6e1b93beab7fac3648fc"><gtr:id>e370902ae10c6e1b93beab7fac3648fc</gtr:id><gtr:otherNames>Gordon AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>58c44f99efcfb4.11720522</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4333E56A-3E0D-42FD-8284-9835EBAC99C3</gtr:id><gtr:title>Statin therapy in critically-ill patients with severe sepsis: a review and meta-analysis of randomized clinical trials.</gtr:title><gtr:parentPublicationTitle>Minerva anestesiologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4077e8c96c3200758e62a77b4651fb05"><gtr:id>4077e8c96c3200758e62a77b4651fb05</gtr:id><gtr:otherNames>Thomas G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0375-9393</gtr:issn><gtr:outcomeId>56de55c291b755.80870417</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A4BE469-3066-437B-A6A3-C57DE4D3A1F7</gtr:id><gtr:title>Simvastatin in the acute respiratory distress syndrome.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae21e9c1839a8b5535f2713c32c95fec"><gtr:id>ae21e9c1839a8b5535f2713c32c95fec</gtr:id><gtr:otherNames>McAuley DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>546272902eb2e3.03187000</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>017702D6-4A32-468B-87E1-6B9B264C2F8B</gtr:id><gtr:title>Statin use and risk of delirium in the critically ill.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac588ec976e6b4c01d6bb3b7feecb88f"><gtr:id>ac588ec976e6b4c01d6bb3b7feecb88f</gtr:id><gtr:otherNames>Page VJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>5462728ed19985.01402601</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_G1002460</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>